[ad_1]
Cell therapy manufacturer Cellares, which last year announced $255 million in Series C funding to complete and launch a new highly automated facility in Somerset County, will open its state-of-the-art facility on Monday. I am prepared.
Serales will be joined by local residents Monday at a ribbon-cutting ceremony at 95 Corporate Drive in Bridgewater (the building that once housed Pfizer) to celebrate its future contributions to the local economy and support for patients in need of cell therapy. We plan to invite high-ranking officials.
The 118,000 square foot manufacturing site is expected to create up to 350 local jobs. The company describes the new site as a “smart factory,” and once completed, it will become the second facility operated by the world’s first integrated development and manufacturing organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing. Become.
“We are excited to welcome Serales to New Jersey’s life sciences capital,” said Somerset County Commissioner Shanelle Robinson. “These are the types of businesses that our economic development team is committed to bringing to Somerset County.”
“The opening of this facility marks a major milestone in Cellares’ mission to accelerate access to life-saving cell therapies to meet the total global patient demand,” said Bridgewater IDMO Smart Factory Senior Vice President and Chief Executive Officer. General Manager John Tomtischen said. “We look forward to partnering with states and local communities to bring online a facility that will manufacture tens of thousands of cell therapy products annually and create 350 job opportunities for highly talented individuals. Masu.”
The facility will seamlessly integrate “advanced robotics, purpose-built technology, and interconnected software” and be “capable of producing 40,000 batches of cell therapy per year,” compared to traditional contract manufacturing and development currently available. An order of magnitude larger than what is possible. organization, or CDMO, operates from facilities of comparable size. This will ultimately allow developers to effectively scale up manufacturing and ensure that patients on waiting lists no longer die while waiting for life-saving cell therapies.
“Selleres not only joins a thriving life sciences industry here, but also recognizes the fact that many of the treatments the world needs come from Somerset County,” said Jessica Paolini, economic development manager for Somerset County. It corroborated this,” he said. “We are investing in the infrastructure essential to growing and sustaining the life sciences, including Raritan Valley Community College, which produces the talent needed by cell and gene therapy companies like Cerales. This includes a recent $3 million investment in a new training program.”
To date, the California-based company has raised a total of approximately $355 million in Series C funding, led by Koch Disruptive Technologies and backed by Bristol-Myers Squibb, DFJ Growth, Willett and others. Advisors and existing investors Eclipse, Tokusei Capital, and 8VC are also investing.
[ad_2]
Source link
